Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2016 ASCO Annual Meeting /
Sequencing analysis with circulating DNA

3rd - 7th Jun 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.16
Views: 1539

Dr Oliver Zill - Guardant Health Inc, Brentwood City, USA

Dr Zill speaks with ecancertv at ASCO 2016 about data from the clinical impact of sequencing circulating tumour DNA (ctDNA) with liquid biopsy techniques.

He reports on sampling somatic genomic profiles of over 15,000 patients with advanced-stage clinical cancer, and using liquid biopsy assays to determine cancer-type-specific frequencies and mutual exclusivity patterns among major driver alterations.

The overall accuracy of ctDNA sequencing in comparison with matched tissue tests was 87% (336/386), and Dr Zill highlights that accuracy increased to 98% when blood and tumour were collected less than six months apart.

He goes on to set out different classes of patient outcomes, and encourages the incorporation of liquid biopsy into patient surveillance on a wider scale.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation